title: Antidepressant treatment outcome depends on the quality of the living environment: a pre-clinical investigation in mice.
abstract: Antidepressants represent the standard treatment for major depression. However, their efficacy is variable and incomplete. A growing number of studies suggest that the environment plays a major role in determining the efficacy of these drugs, specifically of selective serotonin reuptake inhibitors (SSRI). A recent hypothesis posits that the increase in serotonin levels induced by SSRI may not affect mood per se, but enhances neural plasticity and, consequently, renders the individual more susceptible to the influence of the environment. Thus, SSRI administration in a favorable environment would lead to a reduction of symptoms, while in a stressful environment might lead to a worse prognosis. To test this hypothesis, we treated C57BL/6 adult male mice with chronic fluoxetine while exposing them to either (i) an enriched environment, after exposure to a chronic stress period aimed at inducing a depression-like phenotype, or (ii) a stressful environment. Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated. Mice treated with fluoxetine in an enriched condition improved their depression-like phenotype compared to controls, displaying higher saccharin preference, higher brain BDNF levels and reduced corticosterone levels. By contrast, when chronic fluoxetine administration occurred in a stressful condition, mice showed a more distinct worsening of the depression-like profile, displaying a faster decrease of saccharin preference, lower brain BDNF levels and increased corticosterone levels. Our findings suggest that the effect of SSRI on depression-like phenotypes in mice is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.
authors: Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy. branchi@iss.it
authors: Igor
authors: I
authors: Branchi
authors: Sara
authors: S
authors: Santarelli
authors: Sara
authors: S
authors: Capoccia
authors: Silvia
authors: S
authors: Poggini
authors: Ivana
authors: I
authors: D'Andrea
authors: Francesca
authors: F
authors: Cirulli
authors: Enrico
authors: E
authors: Alleva
mesh_terms: D059445:Anhedonia; D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001522:Behavior, Animal / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D019208:Brain-Derived Neurotrophic Factor / Q000378:metabolism; D003345:Corticosterone / Q000097:blood; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology / Q000523:psychology*; D004353:Drug Evaluation, Preclinical; D004777:Environment; D005473:Fluoxetine / Q000494:pharmacology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D012701:Serotonin / Q000378:metabolism; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology*; D013315:Stress, Psychological; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D019208:Brain-Derived Neurotrophic Factor; D003345:Corticosterone; D005473:Fluoxetine; D012701:Serotonin; D017367:Selective Serotonin Reuptake Inhibitors
references: JAMA. 2010 Jan 6;303(1):47-53
references: 20051569
references: Pharmacol Ther. 2008 Jan;117(1):30-51
references: 17949819
references: Psychoneuroendocrinology. 2011 Apr;36(3):415-25
references: 20399565
references: Brain Res. 2004 Oct 22;1024(1-2):183-92
references: 15451381
references: Neuroscience. 2006;137(2):619-25
references: 16310967
references: Neurosci Lett. 2011 Apr 25;494(2):150-4
references: 21385602
references: Neuropsychopharmacology. 2004 Jul;29(7):1321-30
references: 15085085
references: Biol Psychiatry. 2007 Jul 1;62(1):47-54
references: 17123470
references: Community Dent Oral Epidemiol. 2011 Dec;39(6):481-7
references: 21623864
references: Med Sci Monit. 2002 Oct;8(10):BR385-90
references: 12388910
references: Psychopharmacology (Berl). 1997 Dec;134(4):319-29
references: 9452163
references: Lancet. 2013 Feb 2;381(9864):375-84
references: 23219570
references: N Engl J Med. 2008 Jan 17;358(3):252-60
references: 18199864
references: Neuropsychopharmacology. 2004 Nov;29(11):2007-17
references: 15266352
references: Behav Pharmacol. 2006 Feb;17(1):19-29
references: 16377960
references: Prog Neuropsychopharmacol Biol Psychiatry. 2008 Jan 1;32(1):164-77
references: 17826880
references: Arch Gen Psychiatry. 2006 Jan;63(1):50-6
references: 16389196
references: Psychoneuroendocrinology. 2011 Apr;36(3):339-51
references: 20875703
references: Science. 1984 Dec 14;226(4680):1342-4
references: 6334362
references: Biol Psychiatry. 2003 Jul 1;54(1):70-5
references: 12842310
references: Eur J Neurol. 2007 Feb;14(2):e9
references: 17250716
references: Brain Res. 2006 Sep 19;1110(1):221-5
references: 16876769
references: Neuropharmacology. 2003 Sep;45(4):553-63
references: 12907316
references: Neuropsychopharmacology. 2000 Nov;23(5):477-501
references: 11027914
references: Learn Mem. 2006 Mar-Apr;13(2):192-200
references: 16547163
references: Behav Genet. 2008 Jan;38(1):34-43
references: 17955359
references: Front Neuroendocrinol. 2009 Aug;30(3):379-95
references: 19442684
references: Neurosci Biobehav Rev. 2011 Jan;35(3):599-611
references: 20621121
references: Arch Gen Psychiatry. 2009 Aug;66(8):848-56
references: 19652124
references: Cochrane Database Syst Rev. 2004;(1):CD003012
references: 14974002
references: Behav Brain Res. 2009 Mar 2;198(1):199-205
references: 19027796
references: Behav Brain Sci. 2012 Oct;35(5):368
references: 23095389
references: Science. 2008 Apr 18;320(5874):385-8
references: 18420937
references: J Clin Psychiatry. 2003 Dec;64(12):1465-75
references: 14728109
references: Int J Neuropsychopharmacol. 2011 Apr;14(3):405-12
references: 20800012
references: J Neurosci. 2005 Jun 29;25(26):6243-50
references: 15987954
references: Int J Methods Psychiatr Res. 2003;12(3):117-27
references: 12953139
references: Biol Psychiatry. 2008 Sep 15;64(6):527-32
references: 18571629
references: Psychiatry (Edgmont). 2008 Apr;5(4):35-6
references: 19727307
references: Mol Psychiatry. 2009 Aug;14(8):746-54
references: 19455150
references: Nat Rev Neurosci. 2010 Sep;11(9):651-9
references: 20725096
references: Eur J Pharmacol. 2010 Sep 25;643(2-3):180-7
references: 20599917
references: Pharmacopsychiatry. 2008 Mar;41(2):66-71
references: 18311687
references: J Neurosci. 1996 Apr 1;16(7):2365-72
references: 8601816
references: BMJ. 2005 Jul 16;331(7509):155-7
references: 16020858
references: Stress. 2008 Mar;11(2):170-5
references: 18311605
references: Neuropharmacology. 1999 Jul;38(7):1063-73
references: 10428425
references: Am J Psychiatry. 2006 Jan;163(1):28-40
references: 16390886
references: J Neurosci. 2002 Apr 15;22(8):3262-8
references: 11943827
references: Brain Res. 2004 Mar 12;1000(1-2):148-55
references: 15053962
references: Neuropsychopharmacology. 2006 Nov;31(11):2443-8
references: 16641944
references: Biol Psychiatry. 2010 Sep 15;68(6):512-20
references: 20579975
references: Psychoneuroendocrinology. 2010 Jun;35(5):743-51
references: 19945226
references: Physiol Behav. 2002 Apr 15;75(5):765-72
references: 12020742
references: Psychoneuroendocrinology. 2012 Jun;37(6):762-72
references: 21974975
references: Psychoneuroendocrinology. 2004 May;29(4):423-47
references: 14749091
references: J Neurosci Methods. 2009 May 30;180(1):43-51
references: 19427528
references: JAMA. 2008 Sep 3;300(9):1069-71
references: 18768418
references: Nat Rev Drug Discov. 2005 Sep;4(9):775-90
references: 16138108
references: Neuroscience. 2012 Sep 18;220:267-76
references: 22710068
references: Neuropharmacology. 2002 Dec;43(7):1148-57
references: 12504921
references: Neurosci Biobehav Rev. 2012 Feb;36(2):786-98
references: 22206901
references: Soc Psychiatry Psychiatr Epidemiol. 2009 Apr;44(4):272-7
references: 18818858
references: Evid Based Ment Health. 2008 Aug;11(3):66-8
references: 18669671
references: Science. 2011 Dec 23;334(6063):1731-4
references: 22194582
references: Mol Psychiatry. 2009 Aug;14(8):764-73, 739
references: 18982002
references: PLoS Med. 2008 Feb;5(2):e45
references: 18303940
references: Mol Psychiatry. 2004 Oct;9(10):908-15
references: 15241435